LongBio Pharma (Suzhou) Co., Ltd. (1779)

Overview

LongBio Pharma (Suzhou) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai and Changshu, Suzhou, China. Founded in 2020, the company specializes in the in-house discovery and development of biologic therapies aimed at treating allergic and autoimmune diseases. With a strong focus on antibody-based and bi-functional biologic drugs, LongBio Pharma is dedicated to modulating immune pathways with high specificity. The company’s research and development initiatives are directed towards diverse therapeutic areas, including rhinology, dermatology, respiratory, hematology, nephrology, and various other immune-mediated conditions. LongBio Pharma operates within the pharmaceuticals and biotechnology sector, where it serves healthcare providers and patients by providing innovative biologic treatment options intended for specialty and hospital usage. By leveraging proprietary technology platforms and internal R&D capabilities, LongBio Pharma plays a vital role in China's innovative biologics ecosystem while building a diversified clinical pipeline.

Products and Services

• Anti-IgE Antibody

  This investigational asset is designed to target and inhibit IgE-mediated pathways, which play a crucial role in allergic reactions. It aims to provide relief for patients suffering from conditions such as allergic rhinitis and chronic spontaneous urticaria.

• Bi-functional Complement Inhibitors

  These novel biologics are engineered to precisely modulate the complement pathways, which can lead to various complement-driven disorders. Their development focuses on renal and hematologic disorders, aiming to improve patient outcomes in conditions related to aberrant immune responses.

• Therapeutics for Allergic Asthma

  LongBio Pharma is committed to addressing the significant unmet needs in the treatment of allergic asthma through its advanced biologic therapies. The aim is to provide more effective management options for patients through targeted immune modulation.

• Research and Development Services

  The company offers comprehensive R&D services that extend beyond its pipeline to potential collaborators, further fostering innovation in the field of biologics. This includes utilizing their proprietary technology platforms for the co-development of biologics aimed at autoimmune and allergic diseases.